Zavante Therapeutics, Inc. Leadership

Mr. Schroeder currently serves as President, Chief Executive Officer and a Zavante Director. Previously Mr. Schroeder co-founded Cadence Pharmaceuticals in 2004 and served as president, CEO and member of the board of directors until the company's acquisition by Mallinckrodt Pharmaceuticals in 2014 for $1.4 billion. Under his leadership, Cadence raised in excess of $400 million from private and public investors including completion of a successful IPO, and established a strong hospital-based sales and marketing presence in support of its acute care product. Prior to co-founding Cadence he held several roles at Elan Pharmaceuticals including senior vice president of North American Sales and Marketing and vice president and general manager of the Hospital Products Business Unit, a role he also held at Dura Pharmaceuticals before its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb.

Dr. Evelyn Ellis-Grosse J. PhD. is a Chief Scientific Officer at Zavante Therapeutics and is based in United States.

Evelyn Ellis-Grosse, PhD., currently serves as Chief Scientific Officer of Zavante and has worked in clinical research and therapeutic drug development for over 20 years spanning areas of phase 1-4 therapeutic development. Dr. Ellis-Grosse is formerly of Wyeth (Pfizer) where she held positions of increasing responsibilities including AVP and Director of the Global Division of Anti-infective Clinical Research and Development. In this capacity, she defined and implemented strategic goals and priorities for the Infectious Disease therapeutic franchise. She was responsible for scientific and operational planning, management and execution of multiple global drug development programs, including those for targeting MDR pathogens.

Richard Vincent is a CFO at Zavante Therapeutics.

Mr. Schroeder currently serves as President, Chief Executive Officer and a Zavante Director. Previously Mr. Schroeder co-founded Cadence Pharmaceuticals in 2004 and served as president, CEO and member of the board of directors until the company's acquisition by Mallinckrodt Pharmaceuticals in 2014 for $1.4 billion. Under his leadership, Cadence raised in excess of $400 million from private and public investors including completion of a successful IPO, and established a strong hospital-based sales and marketing presence in support of its acute care product. Prior to co-founding Cadence he held several roles at Elan Pharmaceuticals including senior vice president of North American Sales and Marketing and vice president and general manager of the Hospital Products Business Unit, a role he also held at Dura Pharmaceuticals before its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb.

Mr. Schroeder currently serves as President, Chief Executive Officer and a Zavante Director. Previously Mr. Schroeder co-founded Cadence Pharmaceuticals in 2004 and served as president, CEO and member of the board of directors until the company's acquisition by Mallinckrodt Pharmaceuticals in 2014 for $1.4 billion. Under his leadership, Cadence raised in excess of $400 million from private and public investors including completion of a successful IPO, and established a strong hospital-based sales and marketing presence in support of its acute care product. Prior to co-founding Cadence he held several roles at Elan Pharmaceuticals including senior vice president of North American Sales and Marketing and vice president and general manager of the Hospital Products Business Unit, a role he also held at Dura Pharmaceuticals before its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb.